The Last Watchdog
MARCH 17, 2021
Biomedical engineer Dr. Joe Alexander, the former medical director at pharmaceutical giant Pfizer, grabbed a distinguished scientist post, as well. Each key, in turn, can be configured to enable access to a dataset only under certain conditions, i.e. if certain attributes are present.
IBM Big Data Hub
AUGUST 7, 2023
Despite advancements in the pharmaceutical industry and biomedical research, delivering drugs to market is still a complex process with tremendous opportunity for improvement. The ability to seize these advantages is one way that pharmaceutical companies may be able to gain sizable competitive edge.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Reltio
SEPTEMBER 13, 2022
The study reported that a composite customer investing in Reltio's MDM solution achieved a 366% return on investment (ROI) and a total net present value of $13 million over three years, with a payback on their investment within six months once operational. This allows those teams to focus more on higher value-added research and data analysis.
Positively RIM
APRIL 16, 2014
Both presenters and attendees agreed: Big Data is ignored at one’s own peril, and it raises a multitude of questions and ethical dilemmas. Repeatedly, presenters emphasized that Big Data is not “more of the same”. There is certainly more data than before, but the real difference is the analytical algorithms applied to the data.
Data Matters
AUGUST 24, 2018
The Big Data (EX) Working Group heard a presentation from LIMRA regarding how insurers are utilizing consumer data in underwriting life insurance products. Discussion following the presentation focused on stakeholder concerns regarding such use of big data, including the lack of consumer disclosures and confidentiality concerns.
Data Matters
SEPTEMBER 20, 2021
Moody’s Analytics, in collaboration with the American Council of Life Insurers, developed the revised bond factors, which are based on more recent historical data, as the data on which the prior factors were based was approximately 30 years old.
Data Matters
DECEMBER 28, 2020
regulators with an additional analytical tool for conducting groupwide supervision. The White Paper identifies best practices for state insurance regulators in their review of predictive models and analytics filed by insurers to justify rates. The four best practices for regulatory review described in the White Paper are to.
Expert insights. Personalized for you.
223 
Let's personalize your content